SCHEMBL572200

SCHEMBL572200

O=C(O)c1cc(F)cc(Cl)c1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 2/20 0.70
HCAR1 Q9BXC0 2/20 0.59
HCAR2 Q8TDS4 2/20 0.47
TTR P02766 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
TSHR P16473 2/20 0.44
ALOX15 P16050 1/20 0.44
TAS1R3 Q7RTX0 1/20 0.44
TAS1R1 Q7RTX1 1/20 0.44
TAS1R2 Q8TE23 1/20 0.44
GPR139 Q6DWJ6 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
CA9 Q16790 1/20 0.41
CA14 Q9ULX7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29454778 1.00 TPMT (0.70) TPMTHCAR1HCAR2TTRCES2
SCHEMBL69625 0.83 TPMT (0.89) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL28214359 0.83 TPMT (1.00) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL157714 0.83 HCAR1 (0.73) TPMTHCAR1HCAR2TTRCES2
SCHEMBL336433 0.83 HCAR1 (0.73) TPMTHCAR1HCAR2TTRCES2
SCHEMBL23699 0.83 TPMT (1.00) TPMTHCAR1HCAR2TTRRXRA
SCHEMBL29558481 0.82 CES2 (0.46) TPMTHCAR1CES2CES1TAS1R3
SCHEMBL5223999 0.82 CES2 (0.46) TPMTHCAR1CES2CES1TAS1R3
Hydrochloric Acid SCHEMBL6518491 0.80 HCAR1 (0.70) TPMTHCAR1HCAR2TTRCES2
SCHEMBL8023966 0.80 TPMT (0.94) TPMTHCAR1HCAR2TTRRXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3551633-B1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA AS (DK) 2021-03-31 EP claimed
EP-3551633-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP claimed
EP-3551634-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS Leo Pharma A/S (DK) 2019-10-16 EP claimed
WO-2018108231-A1 SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO claimed
WO-2018108230-A1 SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS LEO PHARMA A/S (DK) 2018-06-21 WO claimed
EP-4747239-A1 SMALL MOLECULE PROTEIN DEGRADERS OF KRAS G12D MUTANT Merck Sharp & Dohme LLC (US) 2026-05-27 EP disclosed
US-12338241-B2 Bicyclic sulfones and sulfoxides and methods of use thereof GENENTECH, INC. (US) 2025-06-24 US disclosed
CN-120152713-A Tricyclic aryl derivatives and compositions and methods thereof 昂胜医疗科技公司 2025-06-13 CN disclosed
CN-119947718-A Tricyclic aryl derivatives, and compositions and methods thereof 昂胜医疗科技公司 2025-05-06 CN disclosed
CN-115974872-B Azacyclic derivatives, pharmaceutical compositions thereof and uses thereof 南方科技大学 2025-05-02 CN disclosed
EP-3340988-B1 ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES AFASCI INC (US) 2025-04-09 EP disclosed
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2025-04-01 US disclosed
CN-1382124-A Bicyclic androgen and progesterone receptor modulating compounds and methods LIGAND PHARM INC (US) 2002-11-27 CN disclosed
WO-2002068417-A3 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS SLASSI ABDELMALIK (CA) 2002-11-14 WO disclosed
CN-1379775-A Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists NPS PHARMA INC (US) 2002-11-13 CN disclosed
WO-2002068417-A2 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-09-06 WO disclosed
EP-1210344-A1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2002-06-05 EP disclosed
US-6331640-B1 TREATMENT OF REPERFUSION INJURIES HOFFMANN-LA ROCHE INC. 2001-12-18 US disclosed
WO-2001012627-A1 HETEROPOLYCYCLIC COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS NPS PHARMACEUTICALS, INC. (US) 2001-02-22 WO disclosed
EP-0507576-A1 Polypropylene-based resin compositions TOSOH CORPORATION (JP) 1992-10-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12264147-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 TPMT 724/4885HCAR1 2868/4885HCAR2 2443/4885
US-12338241-B2 Bicyclic sulfones and sulfoxides and methods of use thereof RB1, CCNE2, RPS3A TPMT 924/4885HCAR1 4544/4885HCAR2 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.